Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD – Get Free Report) have been assigned an average rating of “Buy” from the five ratings firms that are presently covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a buy recommendation. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $4.60.
Several equities analysts have recently weighed in on the company. Needham & Company LLC reissued a “buy” rating and set a $4.00 target price on shares of Clearside Biomedical in a research report on Monday, May 13th. Wedbush restated an “outperform” rating and issued a $4.00 target price (down from $5.00) on shares of Clearside Biomedical in a research note on Wednesday, March 13th. StockNews.com lowered Clearside Biomedical from a “hold” rating to a “sell” rating in a report on Friday, May 10th. HC Wainwright reduced their price objective on Clearside Biomedical from $6.00 to $5.00 and set a “buy” rating on the stock in a report on Monday, May 13th. Finally, JMP Securities restated a “market outperform” rating and issued a $5.00 price target on shares of Clearside Biomedical in a report on Wednesday, March 13th.
View Our Latest Stock Report on Clearside Biomedical
Hedge Funds Weigh In On Clearside Biomedical
Clearside Biomedical Trading Up 1.6 %
NASDAQ:CLSD opened at $1.30 on Tuesday. The company has a market capitalization of $97.15 million, a P/E ratio of -2.36 and a beta of 2.36. Clearside Biomedical has a 12 month low of $0.65 and a 12 month high of $2.12. The business’s 50-day moving average is $1.28 and its 200 day moving average is $1.33.
Clearside Biomedical (NASDAQ:CLSD – Get Free Report) last announced its earnings results on Thursday, May 9th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.03). The firm had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $0.98 million. During the same quarter last year, the company earned ($0.15) EPS. On average, research analysts forecast that Clearside Biomedical will post -0.63 earnings per share for the current year.
Clearside Biomedical Company Profile
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
Read More
- Five stocks we like better than Clearside Biomedical
- Business Services Stocks Investing
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- ETF Screener: Uses and Step-by-Step Guide
- MarketBeat Week in Review – 6/24 – 6/28
- Why Invest in High-Yield Dividend Stocks?
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.